Get started
SANTHERA PHARMASANTHERA PHARMASANTHERA PHARMA

SANTHERA PHARMA

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

S3F0 chart


Full chart

S3F0 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪120.59 M‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.435 CHF
Net income (FY)
‪−41.97 M‬ CHF
Revenue (FY)
‪39.12 M‬ CHF
Shares float
‪10.01 M‬
Beta (1Y)
0.82

Employees


Employees (FY)
78
Change (1Y)
+34 +77.27%
Revenue / Employee (1Y)
‪498.31 K‬ CHF
Net income / Employee (1Y)
‪−534.70 K‬ CHF

About SANTHERA N


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Dario Eklund
Website
santhera.com
Headquarters
Pratteln
Founded
1998
ISIN
CH1276028821
FIGI
BBG006M6ZJR9
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. Its product pipeline includes Vamorolone and Lonodelestat. The company was founded by Thomas Meier in 1998 and is headquartered in Pratteln, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

S3F0 news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as S3F0.

Frequently Asked Questions


The current price of S3F0 is 13.016 CHF — it has decreased by −5.99% in the past 24 hours. Watch SANTHERA PHARMA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange SANTHERA PHARMA stocks are traded under the ticker S3F0.
We've gathered analysts' opinions on SANTHERA PHARMA future price: according to them, S3F0 price has a max estimate of 30.00 CHF and a min estimate of 24.00 CHF. Watch S3F0 chart and read a more detailed SANTHERA PHARMA stock forecast: see what analysts think of SANTHERA PHARMA and suggest that you do with its stocks.
S3F0 reached its all-time high on Mar 12, 2025 with the price of 14.762 CHF, and its all-time low was 7.285 CHF and was reached on Oct 11, 2023. View more price dynamics on S3F0 chart.
See other stocks reaching their highest and lowest prices.
S3F0 stock is 6.38% volatile and has beta coefficient of 0.82. Track SANTHERA PHARMA stock price on the chart and check out the list of the most volatile stocks — is SANTHERA PHARMA there?
Today SANTHERA PHARMA has the market capitalization of ‪161.92 M‬, it has decreased by −1.97% over the last week.
Yes, you can track SANTHERA PHARMA financials in yearly and quarterly reports right on TradingView.
SANTHERA PHARMA is going to release the next earnings report on Sep 10, 2025. Keep track of upcoming events with our Earnings Calendar.
SANTHERA PHARMA revenue for the last half-year amounts to ‪25.00 M‬ CHF, despite the estimated figure of ‪25.00 M‬ CHF. In the next half-year revenue is expected to reach ‪21.10 M‬ CHF.
S3F0 net income for the last half-year is ‪−26.71 M‬ CHF, while the previous report showed ‪−15.26 M‬ CHF of net income which accounts for −75.00% change. Track more SANTHERA PHARMA financial stats to get the full picture.
No, S3F0 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 29, 2025, the company has 78 employees. See our rating of the largest employees — is SANTHERA PHARMA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SANTHERA PHARMA EBITDA is ‪−27.73 M‬ CHF, and current EBITDA margin is −70.90%. See more stats in SANTHERA PHARMA financial statements.
Like other stocks, S3F0 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SANTHERA PHARMA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SANTHERA PHARMA technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SANTHERA PHARMA stock shows the buy signal. See more of SANTHERA PHARMA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.